The historical rank and industry rank for Spero Therapeutics's OCF Margin % or its related term are showing as below:
SPRO'
s OCF Margin % Range Over the Past 10 Years
Min: -33283.72 Med: -85.57 Max: -15.91
Current: 13.22
During the past 11 years, the highest OCF Margin % of Spero Therapeutics was -15.91%. The lowest was -33283.72%. And the median was -85.57%.
SPRO's OCF Margin % is ranked better than 78.33% of 960
companies
in the Biotechnology industry
Industry Median: -68.59
vs SPRO: 13.22
Spero Therapeutics OCF Margin % Related Terms
Spero Therapeutics OCF Margin % Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spero Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (SPRO) has a OCF Margin % of 6,148.84% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Spero Therapeutics and its competitors. According to the industry distribution chart, Spero Therapeutics ranks #208 out of 960 companies in the Biotechnology industry, placing it in the top 21.7%.
Is Spero Therapeutics' OCF Margin % too high?
Spero Therapeutics' current OCF Margin % is 6,148.84%. Based on the distribution chart, Spero Therapeutics ranks #208 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' OCF Margin % compare to ORMP and PLYX?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #208 out of 960 companies for OCF Margin %. This places Spero Therapeutics in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current OCF Margin % is 6,148.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $2.02 — trading 90.6% above its estimated fair value. The current OCF Margin % is 6,148.84%. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current OCF Margin % is 6,148.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of $2.02 is trading 90.6% above its estimated GF Value™ of $1.06.
GuruFocus considers Spero Therapeutics to be Significantly Overvalued.
Key valuation signals for SPRO:
OCF Margin %: 6,148.84%
GF Value™: $1.06 vs. price of $2.02 (90.6% above fair value)
No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score
Get the complete analysis for SPRO
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
